Information Provided By:
Fly News Breaks for July 26, 2016
JNJ, COO
Jul 26, 2016 | 05:40 EDT
After surveying 50 domestic optometrists on trends in the contact lens market, Piper Jaffray analyst Matt O'Brien believes the impact from Johnson & Johnson's (JNJ) new monthly product Vita should not be overly impactful to Cooper Companies (COO). In addition, the analyst believes J&J's decision to exit the unilateral pricing policy is causing some optometrists to move share away from the company, with Cooper set to benefit. O'Brien keeps an Overweight rating on Cooper with a $185 price target.
News For COO;JNJ From the Last 2 Days
JNJ
JNJ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.